.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Mallinckrodt
Colorcon
Johnson and Johnson
Cerilliant
US Army
Express Scripts
Teva
Boehringer Ingelheim
Covington

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Diagnosis and treatment of brain tumor
Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
Inventor(s): Ruoslahti; Erkki (Buellton, CA), Laakkonen; Pirjo (Helsinki, FI)
Assignee: Sanford-Burnham Medical Research Institute (La Jolla, CA)
Application Number:14/396,414
Patent Claims:1. A method for targeted therapy in a patient with brain cancer comprising administering to a patient in need of such therapy an effective amount of a pharmaceutical composition comprising anti-mammary-derived growth inhibitor (MDGI) antibody and a cancer chemotherapeutic agent.

2. The method according to claim 1 further comprising combining the targeted therapy with a cancer therapy, wherein the cancer therapy cancer is radiation therapy, surgery, siRNA or shRNA for MDGI to inhibit MDGI expression or function in the brain of the patient, or combinations thereof.

3. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of a taxane, an antracyclin, an alkylating agent, a vinca alkaloid, an anti-metabolite, a platinum agent, a steroid, an antibiotic, a selective estrogen receptor modulator and an antibody cancer therapeutic agent.

4. The method of claim 3, wherein the cancer therapeutic agent is selected from the group consisting of docetaxel, doxorubicin, cisplatin, carboplatin, methotrexate, adriamycin, and trastuzumab.

5. The method of claim 2, wherein the composition further comprises a peptide comprising SEQ ID NO:5 or a variant thereof.

6. The method of claim 5, wherein the anti-MDGI antibody is conjugated to SEQ ID NO:5 or a variant thereof.

7. The method of claim 2, wherein the composition is administered after surgical removal of the brain tumor.

Summary for Patent: ► Subscribe

PCT Information
PCT FiledApril 25, 2013PCT Application Number:PCT/US2013/038219
PCT Publication Date:October 31, 2013PCT Publication Number: WO2013/163431

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe Sanford-Burnham Medical Research Institute (La Jolla, CA) Ruoslahti; Erkki (Buellton, CA), Laakkonen; Pirjo (Helsinki, FI) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Accenture
McKinsey
Teva
Colorcon
Julphar
Farmers Insurance
US Department of Justice
UBS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot